Skip to main content
. 2020 Aug 5;9(16):e017015. doi: 10.1161/JAHA.120.017015

Table 1.

Baseline Characteristics of the Study Population by Time‐Averaged On‐Treatment SBP Categories*

Variables Time‐Averaged On‐Treatment SBP Categories, mm Hg P Value
<120 120 to <130 130 to <140 ≥140
No. 263 2658 5878 6179
Age, y 58.1±7.4 58.8±7.2 59.7±7.4 60.9±7.4 <0.001
Men, n (%) 99 (37.6) 1042 (39.2) 2500 (42.5) 2469 (40.0) 0.005
Body mass index, kg/m2 24.6±3.5 24.6±3.5 24.8±3.6 25.1±3.7 <0.001
Current smoking, n (%) 43 (16.3) 543 (20.4) 1432 (24.4) 1517 (24.6) <0.001
Current alcohol drinking, n (%) 39 (14.9) 581 (21.9) 1481 (25.2) 1482 (24.0) <0.001
Family history of diabetes mellitus, n (%) 13 (4.9) 89 (3.4) 244 (4.2) 207 (3.4) 0.056
Enalapril group, n (%) 139 (52.9) 1332 (50.1) 2907 (49.5%) 3124 (50.6) 0.514
BP, mm Hg
SBP at baseline 147.6±16.1 156.0±16.3 163.6±17.1 175.6±21.2 <0.001
DBP at baseline 90.2±10.5 92.1±10.7 93.5±11.2 96.0±12.7 <0.001
Time‐averaged on‐treatment SBP 117.1±2.7 126.3±2.7 135.1±2.8 148.6±7.7 <0.001
Time‐averaged on‐treatment DBP 76.4±4.8 79.4±5.6 81.9±6.2 85.4±7.9 <0.001
Laboratory results, mmol/L
Total cholesterol 5.3±1.1 5.4±1.1 5.5±1.1 5.5±1.2 <0.001
Triglycerides 1.4 (1.0–1.2) 1.4 (1.0–1.9) 1.4 (1.0–1.9) 1.4 (1.0–1.2) <0.001
Fasting glucose, mg/dL 95.2±11.7 95.6±12.0 96.9±12.4 97.9±12.6 <0.001
Creatinine, μmol/L 66.4±16.7 65.2±15.7 66.2±16.1 65.7±17.2 0.056
Folate, ng/mL 8.1 (5.8–10.4) 8.2 (5.6–10.7) 8.0 (5.6–10.3) 7.9 (5.5–10.3) 0.003
Medication use, n (%)
Antihypertensive drugs 122 (46.4) 1205 (45.3) 2602 (44.3) 2959 (47.9) <0.001
Lipid‐lowering drugs 1 (0.4) 28 (1.1) 44 (0.7) 40 (0.6) 0.202
Antiplatelet drugs 10 (3.8) 74 (2.8) 174 (3.0) 191 (3.1) 0.749

BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure.

*

Continuous variables are presented as mean±SDs or medians (25th percentile–75th percentile). Categorical variables are presented as n (%).